Zhihong Zhang - 17 Mar 2026 Form 3 Insider Report for Burning Rock Biotech Ltd (BNR)

Role
Director
Signature
/s/ Yuheng Huang, Attorney-in-Fact for Zhihong Zhang
Issuer symbol
BNR
Transactions as of
17 Mar 2026
Net transactions value
$0
Form type
3
Filing time
17 Mar 2026, 10:00:11 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zhang Zhihong Director 7720 VIA FRANCESCO UNIT 2, SAN DIEGO /s/ Yuheng Huang, Attorney-in-Fact for Zhihong Zhang 17 Mar 2026 0002114639

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BNR Ordinary Shares 1,061,990 17 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 78,504 $3.33 Direct F1, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 117,755 $3.33 Direct F2, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 78,504 $3.33 Direct F3, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 117,755 $3.33 Direct F4, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 78,504 $3.33 Direct F5, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 117,755 $3.33 Direct F6, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 51,469 $0.000200 Direct F7, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 41,000 $0.000200 Direct F8, F10
holding BNR OPTIONS (RIGHT TO BUY) 17 Mar 2026 Ordinary Shares 56,000 $0.000200 Direct F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 26, 2022, the Reporting Person was granted 78,504 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$2 billion by the fifth anniversary of the date of grant (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.
F2 On September 26, 2022, the Reporting Person was granted 117,755 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$2 billion by the fifth anniversary of the date of grant (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.
F3 On September 26, 2022, the Reporting Person was granted 78,504 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$4 billion by the seventh anniversary of the date of grant (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.
F4 On September 26, 2022, the Reporting Person was granted 117,755 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$4 billion by the seventh anniversary of the date of grant (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.
F5 On September 26, 2022, the Reporting Person was granted 78,504 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$10 billion by the seventh anniversary of the date of grants (the "valuation target"), and (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved.
F6 On September 26, 2022, the Reporting Person was granted 117,755 share options, which will vest once (a) the valuation of the Issuer (based on the 60-day average closing share price of its publicly traded shares) reaches US$10 billion by the seventh anniversary of the date of grants (the "valuation target"), (b) the Reporting Person remains employed by the Issuer at the time when the valuation target is achieved, and (c) the Reporting Person has been employed by the Issuer for five years from the date of grant.
F7 On April 30, 2023, the Reporting Person was granted 102,938 share options, with 50%, 25% and 25% of the granted share options vesting on January 1, 2025, January 1, 2026 and January 1, 2027, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for each year from 2023 to 2026.
F8 On April 30, 2024, the Reporting Person was granted 41,000 share options, with 50%, 25% and 25% of the granted share options vesting on January 1, 2026, January 1, 2027 and January 1, 2028, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for the year of 2024.
F9 On April 30, 2025, the Reporting Person was granted 56,000 share options, with 50%, 25% and 25% on of the granted share options vesting January 1, 2027, January 1, 2028 and January 1, 2029, respectively, subject to: (a) the Reporting Person's continued employment, and (b) the annual performance rating of the Reporting Person reaching at least 3.3 for the year of 2025.
F10 Each share option represents the right to receive, upon exercise, one ordinary share.

Remarks:

Exhibit 24 (Power of Attorney)